Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Ovid Therapeutics Inc. is not a good value stock. Ovid Therapeutics Inc. is not a good growth stock. Ovid Therapeutics Inc. is not very popular among insiders. Ovid Therapeutics Inc. is a mediocre stock to choose.
Log in to see more information.
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare n...
OVID Fundamental Data by TradingView

News

Ovid Therapeutics Elevates Meg Alexander to President and COO
Ovid Therapeutics Elevates Meg Alexander to President and COO

TipRanks Financial Blog Ovid Therapeutics ( ($OVID) ) has issued an announcement. Ovid Therapeutics Inc. has promoted Margaret "Meg" Alexander to President and COO, recognizing her extensi...\n more…

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Globe Newswire NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain...\n more…

Ovid Therapeutics Inc. (NASDAQ:OVID) Given Average Rating of "Moderate Buy" by Brokerages
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Average Rating of "Moderate Buy" by Brokerages

Zolmax Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat Ratings reports...\n more…

Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from Analysts
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from Analysts

Ticker Report Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat Ratings reports. Two...\n more…

Ovid Therapeutics to Present at Upcoming September Investor Conferences
Ovid Therapeutics to Present at Upcoming September Investor Conferences

Globe Newswire NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain...\n more…

Contrasting Ovid Therapeutics (NASDAQ:OVID) & Mural Oncology (NASDAQ:MURA)
Contrasting Ovid Therapeutics (NASDAQ:OVID) & Mural Oncology (NASDAQ:MURA)

Zolmax Ovid Therapeutics (NASDAQ:OVID - Get Free Report) and Mural Oncology (NASDAQ:MURA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two...\n more…